Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer | Oncology
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients - Annals of Oncology
Biomarkers in Lung Cancer: Integration with Radiogenomics Data | IntechOpen
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer | Biomarker Research | Full Text
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis - The American Journal of Pathology
When the MET receptor kicks in to resist targeted therapies | Oncogene
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Overcoming therapy resistance in EGFR-mutant lung cancer | Nature Cancer
MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
c-Met Proto-oncogene | Targeting Overexpression
new-molecular-drivers-in-nsclc-the-role-of-met
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | PNAS
